{
    "nctId": "NCT00128622",
    "briefTitle": "Denileukin Diftitox Followed by Vaccine Therapy in Treating Patients With Metastatic Cancer",
    "officialTitle": "A Phase I Study of Regulatory T Cell Depletion With Denileukin Diftitox Followed by Active Immunotherapy With Autologous Dendritic Cells Infected With CEA-6D Expressing Fowlpox-Tricom in Patients With Advanced or Metastatic Malignancies Expressing CEA",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Colorectal Cancer, Lung Cancer, Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 24,
    "primaryOutcomeMeasure": "Safety as measured by rate of adverse events during study drug treatment",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed malignancy\n\n  * Metastatic disease\n* Tumor expresses carcinoembryonic antigen (CEA), as evidenced by any of the following:\n\n  * At least 50% of tumor expresses CEA by immunohistochemistry (IHC) with \u2265 a moderate intensity of staining\n  * Peripheral blood CEA level \\> 5.0 ng/mL\n  * Tumor known to be universally CEA-positive (e.g., colon or rectal cancer)\n* Measurable or evaluable disease\n* Received or refused prior therapy with a possible survival or palliative benefit AND meets the following disease-specific criteria:\n\n  * Patients with colorectal cancer must have experienced disease progression during \u2265 1 prior palliative chemotherapy regimen for metastatic disease comprising 1 of the following regimens:\n\n    * Fluorouracil or capecitabine AND oxaliplatin\n    * Fluorouracil or capecitabine AND irinotecan\n    * Chemotherapy in combination with bevacizumab\n  * Patients with breast cancer must have experienced disease progression during \u2265 1 prior palliative chemotherapy regimen for metastatic disease comprising 1 of the following regimens:\n\n    * Anthracycline- or taxane-based chemotherapy\n    * Chemotherapy AND trastuzumab (Herceptin\u00ae) (required for patients with tumors overexpressing HER2/neu (i.e., 3+ by IHC or positive by fluorescence in situ hybridization \\[FISH\\])\n  * Patients with lung cancer must have experienced disease progression during \u2265 1 prior palliative chemotherapy regimen for metastatic disease comprising 1 of the following regimens:\n\n    * Platinum-based (e.g., cisplatin or carboplatin) chemotherapy (for chemotherapy-naive patients only)\n    * Taxane-based (e.g., docetaxel or paclitaxel) chemotherapy OR vinorelbine (for patients who received prior chemotherapy)\n  * Patients with pancreatic cancer must have experienced disease progression during prior chemotherapy, including gemcitabine\n  * Patients with other malignancies must have experienced disease progression after prior first-line therapy that would confer a survival or palliative benefit, if such a therapy exists\n\n    * Patients who experienced disease progression during prior first-line palliative chemotherapy must be advised regarding second-line therapy before study enrollment\n* Previously resected brain metastases allowed provided there is no evidence of brain metastasis within the past month by MRI or CT scan\n* No requirement for further systemic chemotherapy for \u2265 3 months\n* Hormone receptor status:\n\n  * Not specified\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* 18 and over\n\nSex\n\n* Male or female\n\nMenopausal status\n\n* Not specified\n\nPerformance status\n\n* Karnofsky 70-100%\n\nLife expectancy\n\n* More than 6 months\n\nHematopoietic\n\n* WBC \u2265 3,000/mm\\^3\n* Hemoglobin \u2265 9 g/dL (transfusion or epoetin alfa allowed)\n* Platelet count \u2265 100,000/mm\\^3\n\nHepatic\n\n* Bilirubin \\< 1.5 mg/dL (\u2264 2.0 mg/dL for patients with Gilbert's syndrome)\n* SGOT and SGPT \\< 1.5 times upper limit of normal\n* Albumin \u2265 3.0 g/dL\n* No active acute or chronic viral hepatitis\n\n  * Hepatitis B surface antigen negative\n  * Hepatitis C negative\n* No other hepatic disease that would preclude study treatment\n\nRenal\n\n* Creatinine \\< 1.5 mg/dL\n* No active acute or chronic urinary tract infection\n\nCardiovascular\n\n* No New York Heart Association class III-IV cardiac disease\n\nImmunologic\n\n* HIV negative\n* No history of autoimmune disease\\*, including, but not limited to, the following:\n\n  * Inflammatory bowel disease\n  * Systemic lupus erythematosus\n  * Ankylosing spondylitis\n  * Scleroderma\n  * Multiple sclerosis\n* No active cytomegalovirus (CMV) disease\n\n  * Patients with CMV-seropositivity are eligible\n* No other active acute or chronic infection\n* No history of allergies to eggs or any component of the study vaccine, denileukin diftitox, or diphtheria toxin NOTE: \\*Patients with a positive anti-nuclear antibody (ANA) \u2264 1:256 with no other evidence of autoimmune disease are eligible\n\nOther\n\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception during and for 4 months after completion of study treatment\n* No acute or chronic skin disorder that would preclude study treatment\n* No other malignancy within the past 5 years except nonmelanoma skin cancer, controlled carcinoma in situ of the cervix, or controlled superficial bladder cancer\n* No psychological or medical impediment that would preclude study compliance\n* No other serious acute or chronic illness that would preclude study treatment\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* See Disease Characteristics\n* Prior vaccine, dendritic cell, or CEA-targeted immunotherapy allowed\n* At least 4 weeks since prior and no other concurrent immunotherapy\n* Concurrent palliative single-agent trastuzumab for breast cancer allowed provided patient has been on therapy for \u2265 3 months before study entry\n\nChemotherapy\n\n* See Disease Characteristics\n* At least 4 weeks since prior and no concurrent chemotherapy\n\nEndocrine therapy\n\n* At least 4 weeks since prior hormonal therapy\n* At least 6 weeks since prior steroid therapy except steroids used as premedication for chemotherapy or contrast-enhanced studies\n* No concurrent steroids, including corticosteroids administered to manage toxic effects from dendritic cell or denileukin diftitox administration\n* Concurrent palliative endocrine therapy for breast cancer allowed provided patient has been on therapy for \u2265 3 months before study entry\n\nRadiotherapy\n\n* At least 4 weeks since prior and no concurrent radiotherapy\n\nSurgery\n\n* See Disease Characteristics\n\nOther\n\n* Recovered from all prior therapy\n* At least 4 weeks since prior investigational drugs or procedures\n* At least 4 weeks since other prior therapy\n* No other concurrent immunosuppressive therapy (e.g., azathioprine or cyclosporine)",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}